[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367212-105":59,"doc-detail-367212-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pan-cancer-analysis-to-characterize-the-clinicopathological-and-genomic-features-of-kras-mutated-patients-in-china","Pan-cancer analysis to characterize the clinicopathological and genomic features of KRAS-mutated patients in China","","Pan-cancer profiling focuses on clinicopathological and genomic characteristics of KRAS-mutated tumors in China, addressing the need to map the KRAS landscape across cancer types. Using next-generation sequencing with a 520-gene panel, the study evaluates KRAS mutations, tumor mutation burden, and microsatellite instability-high status. Analysis of 10,820 samples quantifies mutation prevalence and identifies subtype-specific patterns, linking specific KRAS variants to TMB and MSI-H in defined cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-analysis-to-characterize-the-clinicopathological-and-genomic-features-of-kras-mutated-patients-in-china/367212/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-to-characterize-the-clinicopathological-and-genomic-features-of-kras-mutated-patients-in-china/367212.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What genomic features were investigated for KRAS-mutated patients?","Question",{"text":112,"@type":113},"The study examined KRAS mutations, tumor mutation burden (TMB), and microsatellite instability-high (MSI-H) status using a next-generation sequencing approach.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How frequent were KRAS mutations in the analyzed tumor samples?",{"text":117,"@type":113},"KRAS mutations were found in 19.97% of the 10,820 tumor samples analyzed.",{"name":119,"@type":110,"acceptedAnswer":120},"Which KRAS mutation types showed cancer-type specific patterns?",{"text":121,"@type":113},"KRAS G12D was most common in pancreatic, colorectal, and gastric cancers; KRAS G12V was predominant in uterine cancer; and KRAS G12C was most frequent in lung cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367212,1790195303,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Journal of Cancer Research and Clinical Oncology (2025) 151:94  \n[https://doi.org/10.1007/s00432-025-061](https://doi.org/10.1007/s00432-025-061)18-9  \nPan‑cancer analysis to character the clinicopathological and genomic features of KRAS‑mutated patients in China  \nLiyuan Wu1 · Wei Rao1 · Lei Guo1 · Fanshuang Zhang1 · Weihua Li1 · Jianming Ying1  \nReceived: 12 December 2024 / Accepted: 22 January 2025 / Published online: 27 February 2025 © The Author(s) 2025  \nAbstract  \nPurpose The Kirsten rat sarcoma viral oncogene (KRAS) is the most frequently mutated oncogene in human cancers. Significant advancements have been made in targeted therapy and immunotherapy for this gene in recent years, underscoring the importance of comprehensively understanding the genomic landscape of KRAS across various cancer types.  \nMethods Using next-generation sequencing (NGS) technology and a panel of 520 genes, KRAS mutations, tumor mutation burden (TMB), and microsatellite instability (MSI-H) status were investigated.  \nResults An analysis of 10,820 tumor samples found KRAS mutations in 19.97% of cases. Pancreatic cancer showed the highest prevalence ofKRAS mutations at 73.51%, while colorectal at 41.45%, uterine at 21.23%, and lung cancer at 11.24% . KRAS G12D mutation is most common in pancreatic, colorectal, and gastric cancers, while KRAS G12V mutation is predominant in uterine cancer, and KRAS G12C mutation is most frequent in lung cancer. Significant correlations were found between TMB and KRAS G13D/G12V mutations in colorectal cancer. KRAS G13D notably affected TMB in uterus cancer, while KRAS G12C mutation was linked to high TMB in lung cancer. Moreover, statistical analysis revealed a significant association between KRAS G13D/G12V mutations and MSI-H in colorectal cancer.  \nConclusions KRAS mutations were most frequent in cancers of the digestive, female reproductive, and respiratory systems. Specific KRAS mutations are associated with TMB and MSI in various cancer types.  \nKeywords Malignant tumors · Next-generation sequencing · KRAS mutation · Tumor mutation burden · Microsatellite instability  \nLiyuan Wu and Wei Rao contributed equally to this work and asco-first authors.  \n* Weihua Li[liweihua@cicams.ac.cn](liweihua@cicams.ac.cn)  \n* Jianming Ying [jmying@cicams.ac.cn](jmying@cicams.ac.cn)  \nLiyuan Wu  \n[wuliyuanys@163.com](wuliyuanys@163.com)  \nWei Rao  \n[raow09@163.com](raow09@163.com)  \nLei Guo  \n[guolei0520@163.com](guolei0520@163.com)  \nFanshuang Zhang  \n[fanshuang_zhang@163.com](fanshuang_zhang@163.com)  \n1 Departments of Pathology, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Beijing 100021, China  \nAbbreviations  \nKRAS  \nNGS  \nTCGA  \nCHCAMS  \nPD-L1  \nEGFR  \nTMB  \nMSI  \nICIs  \nNGS  \nPCR  \nFDA  \nNSCLC  \nPDAC  \nCOADREAD  \nSTAD  \nPAAD  \nKirsten rat sarcoma viral oncogene Next-generation sequencing The Cancer Genome Atlas  \nCancer Hospital Chinese academy of medical sciences  \nProgrammed death-ligand-1  \nEpidermal growth factor receptor Tumor mutational burden Microsatellite instability Immune checkpoint inhibitors Next-generation sequencing Polymerase chain reaction Food and drug administration  \nNon-small cell lung cancer  \nPancreatic ductal adenocarcinoma Colon adenocarcinoma/rectum adenocar  \ncinoma esophageal carcinoma Stomach adenocarcinoma Pancreatic adenocarcinoma  \nESCA Esophageal carcinoma  \nCHOL Cholangiocarcinoma  \nLUAD Lung adenocarcinoma  \nLUSC Lung squamous cell carcinoma  \nUCEC Uterine corpus endometrial carcinoma  \nOV Ovarian serous cystadenocarcinoma  \nCESC Cervical squamous cell carcinoma and  \nendocervical adenocarcinoma  \nHNSC Head and neck squamous cell carcinoma  \nTHCA Thyroid carcinoma  \ndMMR Mismatch repair system  \nBackground  \nRAS gene was the first human oncogene identified (Stephen et al. 2014), comprising three principal subtyp","cbCail8kSeVOjMOG","https://ap.wps.com/l/cbCail8kSeVOjMOG","pdf",866671,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n# Background","[{\"question\":\"What genomic features were investigated for KRAS-mutated patients?\",\"answer\":\"The study examined KRAS mutations, tumor mutation burden (TMB), and microsatellite instability-high (MSI-H) status using a next-generation sequencing approach.\"},{\"question\":\"How frequent were KRAS mutations in the analyzed tumor samples?\",\"answer\":\"KRAS mutations were found in 19.97% of the 10,820 tumor samples analyzed.\"},{\"question\":\"Which KRAS mutation types showed cancer-type specific patterns?\",\"answer\":\"KRAS G12D was most common in pancreatic, colorectal, and gastric cancers; KRAS G12V was predominant in uterine cancer; and KRAS G12C was most frequent in lung cancer.\"}]","Pan-cancer analysis to characterize the clinicopathological and genomic features of KRAS-mutated patients in China | PDF",1790169725,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31644eea4c65366aea7c3f145a670ba3.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e84dd708f7c602c88d7dba27f598ef8.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dcea68cb837ec91acc09cf9d87af28c.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39ae806a269bd179c8331dfdaf14323b.webp",980,1301]